Answers are grounded in this paper and cite their sources.
This study reviews the anti-inflammatory potential of cannabidiol (CBD) in the management of type 1 diabetes (T1D). A comprehensive search was conducted across PubMed, Scopus, and ScienceDirect databases using the terms "type 1 diabetes", "cannabidiol", "anti-inflammatory effect", and "CBD". Articles published between 2005 and 2025 were screened, and studies involving animal models that examined CBD as a therapeutic intervention for T1D and reported on its anti-inflammatory effects were included. Of the 62 retrieved articles, only 6 met the predefined inclusion criteria. Although limited in number, the available studies show promising outcomes. CBD demonstrates potential as an adjuvant therapy for T1D due to its immunomodulatory and anti-inflammatory actions. Nonetheless, further research is required to establish safe and effective clinical application protocols.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: